Canertinib

From WikiMD's Food, Medicine & Wellness Encyclopedia

Canertinib (CI-1033) is an investigational pharmaceutical agent under evaluation for its potential in treating various types of cancer. It acts primarily as an irreversible tyrosine-kinase inhibitor, targeting multiple members of the ErbB family of tyrosine kinases.

Canertinib

Mechanism of Action[edit | edit source]

Canertinib exhibits its inhibitory activity by specifically targeting and irreversibly binding to certain tyrosine kinases. The primary targets of Canertinib include:

  • EGFR (Epidermal Growth Factor Receptor): IC50 of 0.8 nM
  • HER-2: IC50 of 19 nM
  • ErbB-4: IC50 of 7 nM

The IC50 values indicate the concentration of the drug required to inhibit 50% of the enzyme's activity, giving a measure of the drug's potency against each kinase.

Drug Interactions[edit | edit source]

OATP1B3 Interaction[edit | edit source]

Canertinib has been identified as a substrate for the transporter OATP1B3 (Organic Anion Transporting Polypeptide 1B3). The interaction with OATP1B3 can influence the hepatic disposition of canertinib, potentially leading to changes in its metabolism and efficacy. This interaction may also pave the way for transporter-mediated drug-drug interactions, thereby affecting the overall pharmacokinetics of canertinib or other co-administered drugs.

It is essential to note that while canertinib is a substrate for OATP1B3, it does not inhibit the activities of both OATP-1B1 and OATP-1B3 transporters. This is crucial in predicting potential drug interactions and the overall safety profile of canertinib.

Clinical Implications[edit | edit source]

As an experimental drug, canertinib is still undergoing clinical trials to determine its safety, efficacy, optimal dosing, and potential indications in the treatment of cancer. Given its mechanism of action, it may provide a therapeutic option for cancers that are driven by the overactivity of the ErbB family of tyrosine kinases, particularly those that express or overexpress EGFR, HER-2, and ErbB-4.

See Also[edit | edit source]

Canertinib Resources
Doctor showing form.jpg
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD